Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

ORION-4 is led by Professor Louise Bowman and Professor Martin Landray at the Clinical Trial Service Unit (CTSU) at the University of Oxford and many doctors and nurses around the UK and the USA are taking part. 

An expert Steering Committee chaired by senior researchers from the University of Oxford and the TIMI Study Group at Brigham and Women’s Hospital in Boston, USA oversees the study. Members include researchers running the study in the UK and the US along with experts in this kind of research. 

An independent committee of experts known as the Data Monitoring Committee also watches over the study during its progress in order to safeguard participants. This committee could stop the study early if there was important new information from this, or other, studies that affected whether the ORION-4 study should continue.

The study is cosponsored by the University of Oxford and Novartis Pharmaceutical Corporation.

Novartis Pharmaceutical Corporation are providing treatment for the study free of charge and are funding the cost of running the study.

The study is funded by Novartis Pharmaceutical Corporation by a grant to the University of Oxford. 

Researchers at the Clinical Trials Service Unit, University of Oxford are supported by funding from the British Heart Foundation, the Medical Research Council and Cancer Research UK.